C4 Therapeutics (CCCC)
NASDAQ:CCCC
Want to see CCCC full AI Analyst Report?
Top Page
C4 Therapeutics
(NASDAQ:CCCC)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.00
▲(2.74% Upside)
Action:ReiteratedDate:04/10/26
The score is held back primarily by weak financial performance (deep losses, ongoing cash burn, and 2025 revenue falling to $0), partially offset by constructive technical momentum and positive corporate developments (expanded Roche deal and multi-year clinical strategy with runway to 2028). Valuation remains constrained by negative earnings and no dividend support.
Positive Factors
Expanded Roche collaboration
A deeper, decade-long Roche partnership materially strengthens non-dilutive funding and validates C4T's degrader expertise. Roche leading development and commercialization shifts late-stage costs off C4, while tiered milestones/royalties create a durable upside stream tied to partner-led product success.
Negative Factors
Persistent negative cash flow
Sustained, large negative operating and free cash flow materially increases financing needs and dilution risk. Without a shift to positive cash generation or secured milestone funding, management must rely on partner payments or capital markets, constraining long-term strategic options.
Read all positive and negative factors
Positive Factors
Negative Factors
Expanded Roche collaboration
A deeper, decade-long Roche partnership materially strengthens non-dilutive funding and validates C4T's degrader expertise. Roche leading development and commercialization shifts late-stage costs off C4, while tiered milestones/royalties create a durable upside stream tied to partner-led product success.
Read all positive factors
C4 Therapeutics (CCCC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$289.81M
Dividend YieldN/A
Average Volume (3M)2.88M
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue Growth-10.57%
EPS Growth1.98%
CountryUS
Employees110
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.18
Shares Outstanding97,578,180
10 Day Avg. Volume4,147,757
30 Day Avg. Volume2,878,552
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue6.23
Enterprise Value/Gross Profit6.56
Enterprise Value/Ebitda-2.07
Forecast
1Y Price Target
$14.50Price Target Upside396.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
C4 Therapeutics Business Overview & Revenue Model
Company Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate ...
How the Company Makes Money
C4 Therapeutics makes money primarily through (1) collaboration and licensing arrangements and (2) to a lesser extent, other operating income; as a clinical-stage company, it has historically not relied on product sales and its ability to generate...
C4 Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.95M | 35.58M | 20.76M | 31.10M | 45.78M |
| Gross Profit | 27.97M | 35.58M | 13.02M | 31.10M | 45.78M |
| EBITDA | -102.91M | -103.37M | -122.10M | -124.28M | -80.25M |
| Net Income | -104.99M | -105.32M | -132.49M | -128.18M | -83.89M |
Balance Sheet | |||||
| Total Assets | 359.07M | 349.60M | 376.45M | 430.84M | 506.76M |
| Cash, Cash Equivalents and Short-Term Investments | 248.54M | 244.90M | 253.68M | 276.15M | 309.28M |
| Total Debt | 59.98M | 65.76M | 70.98M | 87.15M | 42.88M |
| Total Liabilities | 102.49M | 133.62M | 130.34M | 141.61M | 117.16M |
| Stockholders Equity | 256.59M | 215.99M | 246.11M | 289.23M | 389.61M |
Cash Flow | |||||
| Free Cash Flow | -99.30M | -65.34M | -108.55M | -111.44M | -88.24M |
| Operating Cash Flow | -98.69M | -65.16M | -106.84M | -105.94M | -86.97M |
| Investing Cash Flow | -8.60M | -51.27M | 158.35M | 58.42M | -189.34M |
| Financing Cash Flow | 126.40M | 45.34M | 45.49M | 1.15M | 171.40M |
C4 Therapeutics Technical Analysis
Positive
2.92
Price Trends
2.58
Positive
2.41
Positive
2.40
Positive
Market Momentum
0.07
Negative
56.64
Neutral
77.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCCC, the sentiment is Positive. The current price of 2.92 is above the 20-day moving average (MA) of 2.70, above the 50-day MA of 2.58, and above the 200-day MA of 2.40, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 56.64 is Neutral, neither overbought nor oversold. The STOCH value of 77.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCCC.
C4 Therapeutics Risk Analysis
C4 Therapeutics disclosed 73 risk factors in its most recent earnings report. C4 Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
C4 Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $289.81M | -1.51 | -53.83% | ― | -10.57% | 1.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $833.26M | -18.84 | -63.06% | ― | ― | 59.04% | |
48 Neutral | $272.31M | -2.71 | -46.46% | ― | ― | 72.35% | |
43 Neutral | $29.19M | -2.09 | 315.97% | ― | ― | -234.46% | |
40 Underperform | $77.55M | -2.15 | 13.30% | ― | 448.44% | ― |
* Healthcare Sector Average
CCCC
C4 Therapeutics
2.88
1.26
77.78%
SLS
SELLAS Life Sciences Group
4.46
3.05
216.31%
MCRB
Seres Therapeutics
8.10
-1.21
-13.00%
ELDN
Eledon Pharmaceuticals
3.47
0.19
5.64%
TVGN
Tevogen Bio Holdings
7.55
-39.32
-83.89%
ACTU
Actuate Therapeutics, Inc.
2.97
-6.08
-67.18%
C4 Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
C4 Therapeutics Expands Roche Collaboration with New DAC Deal
Positive
Apr 9, 2026
On April 8, 2026, C4 Therapeutics entered a new research collaboration and license agreement with Roche to discover, develop and commercialize degrader-antibody conjugates for two undisclosed oncology targets, with an option for a third. Roche wil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.